Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390, a PI3K/mTOR Dual Inhibitor, for the Treatment of Advanced Solid Tumors With PIK3CA Mutations

NCT06132932 is registered in ClinicalTrials.gov with Shanghai Jiatan Pharmatech Co., Ltd as lead sponsor.

NCT NCT06132932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06132932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390, a PI3K/mTOR Dual Inhibitor, for the Treatment of Advanced Solid Tumors With PIK3CA Mutations
Lead sponsor
Shanghai Jiatan Pharmatech Co., Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
June 3, 2021
Completion date
January 3, 2023
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pik3ca mutation-related tumors